Using blue light to control CAR T cells and destroy tumours
Researchers have created a method to activate CAR T cells with blue LED light to successfully combat solid tumours in mice.
List view / Grid view
Researchers have created a method to activate CAR T cells with blue LED light to successfully combat solid tumours in mice.
Researchers have discovered that an antibody which targets the CD36 protein prevents Tregs from protecting tumours against immunotherapies in mouse models.
An innovative chimeric vaccine containing an Ebola gene that helps the virus evade the immune system has been used to selectively target and kill glioblastoma in mice.
An innovative new vaccine technique, which sensitises the immune system to the genetic signature of APOBEC mutations (often found in cancers), increases the efficacy of immunotherapies.
Researchers have created a CAR T-cell therapy which targets the CD229 molecule expressed on all multiple myeloma cells and killed human tumour cells in mice.
A study has shown that inexpensive nanoparticles can effectively inhibit PD-L1 in cancer cells in the lab and work as well as antibodies, providing a potential alternative immunotherapy.
Researchers have discovered a new type of T-cell receptor that can kill most cancer types while leaving healthy cells unharmed.
A new study shows that the VISTA molecule stops the immune system responding to self-antigens, including those presented by cancer cells, so an anti-VISTA antibody could be a possible therapy.
A murine study found histone deacetylase 3 (HDAC3) inhibitors reverse epigenetic changes caused by CREBBP mutations found in lymphomas and could be developed into a novel therapy.
A new study has revealed that the Siah2 protein is crucial to control Tregs in mice, which can reduce the effectiveness of immunotherapies.
A study has shown that T cells are driven to attack tumours by IL-2 and Blimp-1 in mice, which researchers say could form the basis of cancer therapies.
A study has revealed that activation of syndecan-4 sensory protrusions extending from cells may be a future target for cancer therapy.
A study has shown that using three antibodies with two different mechanisms of action could be a novel way to improve immuno-oncology treatments.
Upregulation of the c-Cbl gene causes degradation of the immune checkpoint protein PD-1 and may provide a possible new avenue for cancer therapies, according to researchers.
CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR…